Works matching IS 2160763X AND DT 2018 AND VI 7


Results: 108
    1
    2
    3
    4
    5
    6
    7
    8
    9

    Issue Information.

    Published in:
    Clinical Pharmacology in Drug Development, 2018, v. 7, p. i, doi. 10.1002/cpdd.621
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16

    Issue Information.

    Published in:
    Clinical Pharmacology in Drug Development, 2018, v. 7, n. 8, p. 795, doi. 10.1002/cpdd.405
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30

    Issue Information.

    Published in:
    Clinical Pharmacology in Drug Development, 2018, v. 7, n. 7, p. 671, doi. 10.1002/cpdd.404
    Publication type:
    Article
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40

    Issue Information.

    Published in:
    Clinical Pharmacology in Drug Development, 2018, v. 7, n. 6, p. 565, doi. 10.1002/cpdd.403
    Publication type:
    Article
    41
    42
    43
    44
    45

    Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.

    Published in:
    Clinical Pharmacology in Drug Development, 2018, v. 7, n. 5, p. 532, doi. 10.1002/cpdd.427
    By:
    • Tan, Eng‐Huat;
    • Lim, Wan‐Teck;
    • Ahn, Myung‐Ju;
    • Ng, Quan‐Sing;
    • Ahn, Jin Seok;
    • Shao‐Weng Tan, Daniel;
    • Sun, Jong‐Mu;
    • Han, May;
    • Payumo, Francis C.;
    • McKee, Krista;
    • Yin, Wei;
    • Credi, Marc;
    • Agarwal, Shefali;
    • Jac, Jaroslaw;
    • Park, Keunchil
    Publication type:
    Article
    46
    47
    48
    49